Vineet Laboratories Announces Rights Issue of ₹29.96 Crore at ₹30 Per Share
Vineet Laboratories is launching a rights issue of ₹29.96 crore, offering 99,87,258 equity shares at ₹30 each. The record date is December 23, 2025. The issue opens on January 1, 2026, and closes on January 21, 2026. Shareholders will receive 13 rights shares for every 12 held.
A rights issue of this size can impact the company's capital structure and potentially dilute existing shareholders' stakes, but it also provides capital for growth.
The announcement details a rights issue, which is a form of equity fundraising that can be positive for a company's growth and financial position.
Vineet Laboratories Limited has announced details of its upcoming Rights Issue, approved by the Rights Issue Committee of the Board of Directors on December 17, 2025. The company plans to issue 99,87,258 fully paid-up Equity Shares of face value ₹10 each, at a price of ₹30 per share, including a premium of ₹20. This rights issue aims to raise an aggregate amount of ₹29,96,17,740, assuming full subscription.
The Rights Issue will be offered at a ratio of 13 Rights Equity Shares for every 12 Equity Shares held by eligible shareholders as of the record date. The record date for determining entitlement to the rights has been set for December 23, 2025.
The Rights Issue period is scheduled to open on January 1, 2026. The last date for on-market renunciation is January 16, 2026, and for off-market renunciation is January 20, 2026. The Rights Issue is expected to close on January 21, 2026, although the company reserves the right to extend the issue period by up to 30 days.
Prior to the rights issue, the company has 92,19,008 equity shares outstanding. Upon full subscription, the total outstanding equity shares are expected to increase to 1,92,06,266.
The Rights Issue Committee meeting commenced at 2:00 PM and concluded at 3:00 PM on December 17, 2025. The Letter of Offer will be filed with the BSE, NSE, and SEBI, and dispatched to eligible shareholders in due course.
What to do with a filing like this
Vineet Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vineet Laboratories Limited. Read the original for the full detail.